ProPhase (PRPH): Rasio kapitalisasi pasar marang pendapatan

The development of ProPhase Labs, Inc. (PRPH) relies on scaling genetic research and maintaining resilience to market cycles through innovation. The company's historical P/S ratio visualizes the balance between the defensive value margin and sales growth rates, while the 0.20 metric confirms the current valuation level. High confidence in diagnostic quality solidifies its status as a dynamic player in the healthcare sector.

The P/S multiple for ProPhase Labs, Inc. (PRPH) is calculated by dividing its market capitalization by its annual revenue. This ratio determines the cost of one dollar of sales, signaling whether the asset is overvalued or undervalued. For a high-tech genomic sequencing ecosystem with high customer retention costs, this metric reflects market confidence in the scalability of AI platforms. The price action of the P/S multiple allows for an assessment of the monetization efficiency of diagnostic services.